Industry News
Biotechnology Industry News
Following the launch of its Wegovy…
Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as $2.1 billion to next-gen delivery mechanisms for its metabolic portfolio.
A year after Abcuro raised $200…
A year after Abcuro raised $200 million to fund a phase 2/3 muscle disease trial of its anti-KLRG1 antibody, the study has flunked all its main goals.
Novo Nordisk and its Chinese…
Novo Nordisk and its Chinese partner have reported up to 19.7% weight loss in patients who took their triple agonist for 24 weeks, illuminating a potential path forward for the Danish drugmaker as it tries
GSK is continuing to bolster its…
GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from China’s Frontier Biotechnologies.
Protara Therapeutics has touted a…
Protara Therapeutics has touted a 66% complete response rate for its cell therapy among certain bladder cancer patients as “impressive,” despite this rate halving at the 12-month mark.
Galapagos took a 228 million euro…
Galapagos took a 228 million euro ($269 million) hit last year as it began to close its cell therapy business, but the Belgian biopharma is confident it can stabilize its finances by the end of
Slate Medicines has emerged with…
Slate Medicines has emerged with hopes of cracking the code for delivering an injectable novel drug class to prevent migraines, an area where others—such as Eli Lilly and Amgen—have previously failed.
The average upfront value for a…
The average upfront value for a licensing deal between a Western biopharma company and its Chinese counterpart increased from $52 million to $172 million between 2022 and early 2026, according to data shared with Fierce
Astellas is aiding Vir…
Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager for prostate cancer.
After teasing a new regulatory…
After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, like the one
Rome-based Angelini Pharma has…
Rome-based Angelini Pharma has inked a multi-year deal with Massachusetts biotech Quiver Bioscience that is designed to advance novel therapies for genetic epilepsies and could garner up to $120 million in milestone payments for the
A phase 3 study of Gossamer…
A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension has missed its primary endpoint, triggering a 77% crash in the biotech’s share price.
Generate:Biomedicines is hoping to…
Generate:Biomedicines is hoping to raise up to $425 million via an IPO, with the proceeds expected to bankroll its lead antibody through respiratory disease trials.
Gilead has struck a deal to buy…
Gilead has struck a deal to buy Arcellx for $7.8 billion to take full control of a CAR-T cell therapy that is on the cusp of approval.
MoonLake Immunotherapeutics has…
MoonLake Immunotherapeutics has kicked off a year of readouts for its much-hyped inflammatory disease prospect with a midstage win in a type of arthritis.
In an effort to battle against…
In an effort to battle against what members feel is an existential threat to their businesses, a group of 10 domestic biotech companies has launched the Midsized Biotech Alliance of America with a focus on
Ionis Pharmaceuticals has pulled…
Ionis Pharmaceuticals has pulled the plug on an early investigational treatment for Alzheimer’s disease in people with Down syndrome, marking another setback for a group of patients who are both at higher risk for the
After an FDA rejection of its…
After an FDA rejection of its spinocerebellar ataxia therapy, Biohaven was forced to rethink its strategy—cutting R&D spend by 60% and channeling the spirit of a scrappy startup again as it zeroes in on obesity.
Four years after he resigned as…
Four years after he resigned as chief medical officer at Novartis in the wake of a restructuring at the Big Pharma, John Tsai, M.D., has taken up a similar role at Daiichi Sankyo.
As Candel Therapeutics gears up…
As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW Investments has stepped in with $100 million to bankroll the launch.